Regeneron's bone disorder drug reduces bone lesions in mid-stage study
Reuters: Health
Regeneron Pharmaceuticals Inc said on Thursday its experimental treatment for a very rare genetic disorder proved more effective than placebo in reducing bone lesions.
Subscribe to:
Post Comments (Atom)
Subscribe UsPopular Posts
|
No comments:
Post a Comment